We hypothesized that if resistance to JQ1 provided by FBXW7 S462P occurs through BRAF signaling then specific inhibition of BRAF or the downstream ERK/MEK pathway should impede tumor growth advantage. The gene discussed is BRAF; the disease is neoplasm.